# Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

> **NCT03446573** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 743 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DTG + 3TC
- **DRUG:** TAF based regimen (TBR)

## Key facts

- **NCT ID:** NCT03446573
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-18
- **Primary completion:** 2019-05-20
- **Final completion:** 2022-05-03
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446573, "Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03446573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*